Compare Vaxcyte Inc. Common Stock (PCVX) vs Personalis Inc. Common Stock (PSNL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Personalis Inc. Common Stock — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B), while Personalis Inc. Common Stock trades at $16.14 (market cap $1.69B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 6.2× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is more actively traded (3,817,236 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Personalis Inc. Common Stock for 0 Days on average.
| PCVX | PSNL | |
|---|---|---|
Market Cap | $10.51B | $1.69B |
Volume | 2,644,694 | 3,817,236 |
Sector | Health | Health |
52-Week High | $73.82 | $18.38 |
52-Week Low | $40.32 | $5.04 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $9.14B | $1.52B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Personalis Inc. Common Stock
Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →
